Omega Therapeutics (OMGA) Appoints Richard N. Kender to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
June 24, 2024 7:00 AM EDTCAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (Omega), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its Board of Directors following its annual meeting of stockholders. Mr. Kenders industry knowledge and proven expertise in corporate finance and business development spanning both large pharmaceutical and emerging biotech companies will be instrumental in supporting the Companys business objectives.
Richard has had a long and impressive career in the industry and brings deep... More
